MultiplexDX develops multiplexed diagnostic kits that utilize molecular biology and histopathological methods to provide accurate and quantitative cancer diagnostics, specifically targeting breast cancer. By offering specialized custom oligonucleotides, the company aims to eliminate cancer misdiagnosis and improve treatment outcomes for oncology patients.
Funding
$12.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer diagnostic methods can suffer from inaccuracies and lack the ability to provide quantitative data, potentially leading to misdiagnosis and suboptimal treatment decisions, particularly in complex diseases like breast cancer. Traditional diagnostic approaches may also lack the resolution to assess biomarker expression at the single-cell level, hindering personalized treatment strategies.
Solution
MultiplexDX develops and provides multiplexed diagnostic kits that leverage molecular biology and histopathological techniques to deliver accurate and quantitative cancer diagnostics. Their core offering, Multiplex8+, combines RNA-based visualization and sequencing technologies into a single test, enabling effective and personalized treatment strategies for breast cancer. In addition to cancer diagnostics, MultiplexDX offers custom oligonucleotide synthesis and a range of RNA sequencing and bioinformatics services. The company also provides diagnostic kits for infectious diseases, including a suite of RT-qPCR-based kits for COVID-19 detection and variant identification.
Target Audience
MultiplexDX serves clinical diagnostic laboratories, research institutions, and biopharmaceutical companies requiring precise and quantitative diagnostic tools for cancer and infectious diseases.
Features
- Multiplex8+: A breast cancer diagnostic test combining RNA-based visualization and sequencing for personalized treatment.
- Custom Oligonucleotide Synthesis: Synthesis of aptamers, siRNA, miRNA, qPCR probes, and oligonucleotide triphosphates.
- RNA Sequencing Services: Small RNA library preparation compatible with Illumina sequencing.
- FullRNAlook: Simplified RNA FISH protocol with multi-labeled probes for room temperature hybridization.
- NGS & Bioinformatics: Services including RNA sequencing library preparation, Illumina and Oxford Nanopore sequencing, genome assembly, gene expression analysis, and data visualization.
- COVID-19 Diagnostic Kits: A range of RT-qPCR kits for SARS-CoV-2 detection, including rapid, superplex, multivariant, and allplex assays.
- Infectious Disease Diagnostics: Antigens for the detection of antibodies against Chlamydia and Coxiella burnetii.